Skip to main content
Log in

Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Stroke prevention in atrial fibrillation (AF) has been challenging over decades, mostly due to a number of difficulties associated with oral vitamin K antagonists (VKAs), which have been the most effective stroke prevention treatment for a long time. The oral direct thrombin inhibitors (e.g., dabigatran) and oral direct inhibitors of factor Xa (e.g., rivaroxaban, apixaban) have emerged recently as an alternative to VKAs for stroke prevention in AF. These drugs act rapidly, and have a predictable and stable dose-related anticoagulant effect with a few clinically relevant drug-drug interactions. The novel oral anticoagulants are used in fixed doses with no need for regular laboratory monitoring of anticoagulation intensity. However, each of these drugs has distinct pharmacological properties that could influence optimal use in clinical practice.

The following phase 3 randomized trials with novel oral anticoagulants versus warfarin for stroke prevention in AF have been completed: the Randomized Evaluation of Long-term Anticoagulant therapy (RE-LY) trial with dabigatran, the Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial with rivaroxaban, and the Apixaban for Reduction of Stroke and Other Thromboembolism Events in Atrial Fibrillation (ARISTOTLE) trial with apixaban. Moreover, the Apixaban Versus Acetylsalicylic Acid to prevent Strokes (AVERROES) trial included patients with AF who have failed or were unsuitable for warfarin, and compared apixaban versus aspirin for stroke prevention in AF. Overall, apixaban has two large trials for stroke prevention in AF showing benefits not only over warfarin, but also over aspirin among those patients who have failed or refused warfarin. In the ARISTOTLE trial, apixaban was superior to warfarin in the reduction of stroke or systemic embolism, major bleeding, intracranial hemorrhage, and all-cause mortality, with a similar reduction in the rate of ischemic stroke and better tolerability. When compared with aspirin in the AVERROES trial, apixaban was associated with more effective reduction of stroke, a similar risk of major bleeding, and better tolerability.

In this review article, the authors summarize the current knowledge on novel oral anticoagulants and discuss the clinical aspects of their use for stroke prevention in AF, with particular emphasis on apixaban.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.

    PubMed  Google Scholar 

  2. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation. A meta-analysis. Arch Intern Med. 2012;172:623–631.

    Article  Google Scholar 

  3. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84–91.

    Article  PubMed  Google Scholar 

  4. Nieuwlaat R, Capucci A, Lip GYH, et al.; on behalf the Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026.

    Article  PubMed  CAS  Google Scholar 

  5. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.

    Article  PubMed  CAS  Google Scholar 

  6. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968–977.

    Article  PubMed  CAS  Google Scholar 

  7. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32:2282–2289.

    Article  PubMed  CAS  Google Scholar 

  8. Matchar DB, Jacobson A, Dolor R, et al; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363: 1608–1620.

    Article  PubMed  CAS  Google Scholar 

  9. Anderson JL, Horne BD, Stevens SM, et al. Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing: CoumaGen-II. Circulation. 2012; [Epub ahead of print].

  10. Bussey HI. Transforming oral anticoagulation by combining international normalized ratio (INR) self testing and online automated management. J Thromb Thrombolysis. 2011;31:265–274.

    Article  PubMed  CAS  Google Scholar 

  11. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151.

    Article  PubMed  CAS  Google Scholar 

  12. Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.

    Article  PubMed  CAS  Google Scholar 

  13. Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.

    CAS  Google Scholar 

  14. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.

    Article  PubMed  CAS  Google Scholar 

  15. Sorbera LA, Bozzo J, Castaner J. Dabigatran/dabigatran etexilate. Drugs Fut. 2005;30:877–885.

    Article  CAS  Google Scholar 

  16. Coordinating Committee; De Caterina R, Husted S, Wallentin L, et al. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper. J Am Coll Cardiol. 2012;59:1413–1425.

    Article  PubMed  Google Scholar 

  17. Huisman MV, Lip GYH, Diener H, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; [Epub ahead of print].

  18. Van Ryn J, Stangier J, Haertter S, Liesenfeld K, Wienen W, Feuring M. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulation activity. Thromb Haemost. 2010;103:1116–1127.

    Article  PubMed  Google Scholar 

  19. Pengo V, Crippa L, Falanga A, et al.; Italian Federation of Thrombosis Centers. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868–876.

    Article  PubMed  CAS  Google Scholar 

  20. Errikson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22.

    Article  Google Scholar 

  21. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol. 2012;26:27–32.

    Article  PubMed  CAS  Google Scholar 

  22. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87:S141–S145.

    Article  PubMed  CAS  Google Scholar 

  23. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–1579.

    Article  PubMed  CAS  Google Scholar 

  24. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107:253–259.

    Article  PubMed  CAS  Google Scholar 

  25. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl.):44S–88S.

    Article  Google Scholar 

  26. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–1876.

    Article  PubMed  CAS  Google Scholar 

  27. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669–676.

    Article  PubMed  CAS  Google Scholar 

  28. Ezekowitz MD, Wallentin L, Connolly SJ, et al.; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122:2246–2253.

    Article  PubMed  CAS  Google Scholar 

  29. Wallentin L, Yusuf S, Ezekowitz MD, et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.

    Article  PubMed  CAS  Google Scholar 

  30. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131–136.

    Article  PubMed  CAS  Google Scholar 

  31. Diener HC, Connolly SJ, Ezekowitz MD, et al.; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157–1163.

    Article  PubMed  CAS  Google Scholar 

  32. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–2372.

    Article  PubMed  CAS  Google Scholar 

  33. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–2394.

    Article  PubMed  CAS  Google Scholar 

  34. Banerjee A, Lane DA, Torp-Pedersen C, Lip GYH. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a “real world” atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost. 2012; 107:584–589.

    Article  PubMed  CAS  Google Scholar 

  35. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; [Epub ahead of print].

  36. Artang R, Rome E, Vidaillet H. Dabigatran and myocardial infarction, drug or class effect. Meta-analysis of randomized trials with oral direct thrombin inhibitors. J Am Coll Cardiol. 2012;59;571.

    Article  Google Scholar 

  37. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969–1974.

    Article  PubMed  Google Scholar 

  38. Camm AJ, Kirchof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.

    Article  PubMed  Google Scholar 

  39. Wann LS, Curtis AB, Ellenbogen KA, et al.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144–1150.

    Article  PubMed  Google Scholar 

  40. Skanes AC, Healey JS, Cairns JA, et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–136.

    Article  PubMed  Google Scholar 

  41. Lip GYH, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Thromb Haemost. 2010;103:13–28.

    Article  PubMed  CAS  Google Scholar 

  42. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011;106:572–584.

    Article  PubMed  CAS  Google Scholar 

  43. Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost. 2011;106:569–571.

    Article  PubMed  CAS  Google Scholar 

  44. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.

    Article  PubMed  CAS  Google Scholar 

  45. Alexander JH, Lopes RD, James S, et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.

    Article  PubMed  CAS  Google Scholar 

  46. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168–1174.

    Article  PubMed  CAS  Google Scholar 

  47. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23:264–268.

    Article  PubMed  Google Scholar 

  48. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1–11.

    PubMed  Google Scholar 

  49. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011; [Epub ahead of print].

  50. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908–919.

    Article  PubMed  CAS  Google Scholar 

  51. Ahrens I, Lip GYH, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104:49–60.

    Article  PubMed  CAS  Google Scholar 

  52. Lip GY, Rasmussen LH, Olsson SB, et al.; Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009;30:2897–2907.

    Article  PubMed  CAS  Google Scholar 

  53. Lip GY, Rasmussen LH, Olsson SB, et al.; Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res. 2011;127:91–99.

    Article  PubMed  CAS  Google Scholar 

  54. Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs. 2011;71:1503–1526.

    Article  PubMed  CAS  Google Scholar 

  55. Partida RA, Giugliano RP. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiol. 2011;7:459–470.

    Article  PubMed  CAS  Google Scholar 

  56. Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925–934.

    Article  PubMed  CAS  Google Scholar 

  57. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–641.

    Article  PubMed  CAS  Google Scholar 

  58. Ellis DJ, Usman HM, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  59. Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011;51:561–574.

    Article  PubMed  CAS  Google Scholar 

  60. Eriksson BI, Dahl OE, Lassen MR, et al.; Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6:457–463.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tatjana S. Potpara.

Additional information

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Potpara, T.S., Polovina, M.M., Licina, M.M. et al. Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban. Adv Therapy 29, 491–507 (2012). https://doi.org/10.1007/s12325-012-0026-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-012-0026-8

Keywords

Navigation